Pharma Pulse 2/6/25: The Blue Jacket Fashion Show, Gold Bagging & more

The Blue Jacket Fashion Show

Biljana Naumovic, president of US Oncology Solid Tumor at Johnson & Johnson, spoke with Pharmaceutical Executive about her work with Johnson & Johnson to spread awareness around the importance of early diagnosis for prostate cancer. According to her, this cancer is one of the leading causes of death in men and is often missed during the early stages due to a lack of proper testing.

Gold Bagging: Setting the Gold Standard for Patients

Gold bagging integrates health system-owned specialty pharmacies with clinical workflows to enhance safety, efficiency, outcomes, and patient experience.

Jim Chanos Says Biggest Risk for Markets Is DeepSeek-Like Event

Legendary short seller Jim Chanos says no one can see the biggest risks facing US markets over the next six to 12 months — because the challenges are going to be unpredictable events, like last month’s DeepSeek collapse that wiped out roughly $1 trillion in market value from US stocks.

Flatiron Health and Exact Sciences Partner to Advance Clinical Evidence Generation for Molecular Residual Disease Testing

Flatiron Health and Exact Sciences are entering a strategic partnership aimed at accelerating clinical evidence generation for Exact Sciences’ molecular residual disease test, Oncodetect^TM. The partnership leverages Flatiron’s clinical research platform to study a broad range of solid tumor types. Their first patient is already enrolled.

Nicholas Saraceno on LinkedIn

Thanks for the time, Jenna! We also discussed the key challenges preventing the United States from meeting the FDA’s forecast of 10 to 20 #CGT approvals per year by 2025, the need for continued investment by the #FDA in reviewers and staff to support clinical reviews, and much more, which'll be going live in the coming weeks.

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs